Icon (NASDAQ:ICLR) Stock Price Up 10.2% – Here’s Why

Posted by George Bondi on May 28th, 2026

Shares of Icon Plc (NASDAQ:ICLR – Get Free Report) rose 10.2% on Thursday . The stock traded as high as $128.06 and last traded at $130.54. Approximately 546,197 shares changed hands during mid-day trading, a decline of 65% from the average daily volume of 1,567,196 shares. The stock had previously closed at $118.45.

Analysts Set New Price Targets

ICLR has been the subject of several research analyst reports. Royal Bank Of Canada initiated coverage on Icon in a research report on Monday, May 18th. They issued a “sector perform” rating and a $123.00 price objective for the company. BMO Capital Markets raised Icon from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $100.00 to $130.00 in a research report on Thursday, March 26th. Citigroup lowered their price objective on Icon from $200.00 to $120.00 and set a “neutral” rating for the company in a research report on Wednesday, March 11th. Jefferies Financial Group set a $135.00 target price on Icon and gave the company a “buy” rating in a research note on Monday, February 23rd. Finally, Rothschild & Co Redburn set a $100.00 target price on Icon and gave the company a “neutral” rating in a research note on Tuesday, February 17th. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, Icon has a consensus rating of “Hold” and a consensus price target of $147.67.

Check Out Our Latest Stock Analysis on Icon

Icon Price Performance

The firm has a market cap of $11.08 billion, a price-to-earnings ratio of 18.59, a P/E/G ratio of 2.97 and a beta of 1.23. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.06 and a current ratio of 1.06. The business has a 50 day simple moving average of $111.55 and a 200-day simple moving average of $141.66.

Icon (NASDAQ:ICLR – Get Free Report) last released its quarterly earnings results on Wednesday, May 27th. The medical research company reported $2.52 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.14 by ($0.62). The company had revenue of $2.11 billion for the quarter, compared to analyst estimates of $1.98 billion. Icon had a net margin of 7.40% and a return on equity of 10.58%. Icon’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same quarter last year, the firm posted $3.43 EPS. Icon has set its FY 2026 guidance at 10.000-11.000 EPS. Equities research analysts expect that Icon Plc will post 11.53 earnings per share for the current year.

Hedge Funds Weigh In On Icon

Institutional investors have recently added to or reduced their stakes in the stock. Toth Financial Advisory Corp bought a new position in Icon during the fourth quarter valued at about $27,000. EFG International AG purchased a new position in Icon in the fourth quarter valued at approximately $27,000. Ameriflex Group Inc. purchased a new position in Icon in the third quarter valued at approximately $33,000. Abound Financial LLC purchased a new position in Icon in the fourth quarter valued at approximately $54,000. Finally, Johnson Financial Group Inc. purchased a new position in Icon in the third quarter valued at approximately $71,000. Institutional investors own 95.61% of the company’s stock.

Icon Company Profile

(Get Free Report)

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.